The Foundation is pleased to welcome David R. Goode, a highly acclaimed industrial leader, to its Council, a group of passionate individuals who collaborate with the Board of Directors and Foundation staff to help build awareness and raise funds for focused ultrasound.
“David has great enthusiasm for the potential of focused ultrasound and is eager to share his ideas and vast network to help advance this therapeutic technology,” said Foundation Chairman Neal F. Kassell, MD. “He will be a tremendous champion for the focused ultrasound community. We are fortunate to have him on the team.”
David retired from Norfolk Southern after 13 years as Chairman and CEO. In addition to the railroad, he served as director for several companies, including Caterpillar, Delta Air Lines, Texas Instruments, and Georgia Pacific. David has been an advocate for the arts, as well, and was national chair for the Business Committee for the Arts.
He is currently a Trustee of the Virginia Museum of Fine Arts and is an Emeritus Trustee of the Thomas Jefferson Foundation, which owns and operates Monticello, where he was Vice Chairman for several years."
David has a personal interest in revolutionizing standard of care treatments, particularly for prostate disease and glioblastoma (GBM). Focused ultrasound treatment for destroying diseased prostate tissue is available and approved by the US Food and Drug Administration, and multiple research projects are underway that open the blood-brain barrier to help deliver chemotherapy more efficiently to patients with GBM.
“I’m amazed at the potential of focused ultrasound to transform how diseases are treated and managed, thereby improving the quality of life of so many patients,” David said. “This field is full of possibilities and I am excited to be involved.”